Fintel reports that on April 1, 2025, William Blair upgraded their outlook for Nayax (NasdaqGS:NYAX) from Market Perform to ...

William Blair reissued their market perform rating on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research report ...

Equities researchers at William Blair issued their FY2028 earnings estimates for Tempest Therapeutics in a research report ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

William Blair analyst Margaret Kaczor maintained a Hold rating on Neuronetics (STIM – Research Report) today. The company’s shares closed ...

Investing.com -- William Blair remains optimistic on Tesla (NASDAQ: TSLA) despite recent setbacks, forecasting that shares ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

In a report released today, Ryan Merkel from William Blair maintained a Buy rating on Acuity Brands (AYI – Research Report). The company’s ...

Much of the attention this week for markets and economists will center on the rollout of President Donald Trump’s tariffs.

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

Tesla shares fell more than 5% on Wednesday, ending the EV maker's blistering rebound out of a prolonged slump.

As Klarna wins installment lending for the retail giant's OnePay app, rival Affirm seeks to downplay the loss.